中国肺癌原创临床研究阶段汇总

Lancet Oncol  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Li Zhang (2012)

Lancet Oncol  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Li Zhang (2013)

J Thorac Oncol  Final overall survival results from a phase III, randomized,

placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)  Li Zhang (2015)

Medicine  Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung（C-TONG 0807）：an open-label，single arm，multicenter phase II study  Li Zhang (2015)

J Thorac Oncol  First-in-human phase I study of AC0010, a mutant-selective EGFR Inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance  Li Zhang (2018)

Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial   Li Zhang (2018)

J Clin Pharmacol Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: A phase 1 study  Li Zhang (2018)

Clin Transl Med Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer  Li Zhang (2019)

Lancet Respir Med  Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial  Li  Zhang (2019)

Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Li  Zhang (2019)

Transl Lung Cancer Res  Biosimilar candidate IBI305 pluspaclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer  Li Zhang (2020)

J Thorac Oncol  Efficacy and safety of Sintilimab plus Pemetrexed and Platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by Innov ENT anti-PD-1-11) Li Zhang (2020)

J Thorac Oncol Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706)  Li Zhang (2021)

J Thorac Oncol Decoding the evolutionary response to Ensartinib in ALK-positive non-small-cell lung cancer patients by dynamic circulating tumor DNA sequencing  Li Zhang (2021)

Ann Transl Med Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial Li Zhang (2021)

附鼻咽癌部分

J Clin Oncol Phase III study comparing standard radiotherapy with or without weekly Oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results  Li Zhang (2005)

Cancer Chemother Pharmacol Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy Li Zhang (2008)

Eur J Cancer  Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastase Li Zhang (2011)

Oral Oncol A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma  Li Zhang (2012)

Cancer Chemother Pharmacol Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy  Li Zhang (2012)

Lancet Gemcitabine plus cisplatin versus fluorouracilplus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial  Li Zhang (2016)

BMC Cancer   Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as treatment for metastatic nasopharyngeal carcinoma Li Zhang (2016)

Lancet Oncol Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials  Li Zhang (2018)

Oncologist  A phase I/II open-label study of Nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors  Li Zhang (2019)

Lancet Oncol Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyneal carcinoma （CAPTAIN-1s）：a multicentre，randomised，double-blind，phase 3 trial  Li Zhang (2021)